A dual response nano-carrier to hypoxia and pH, drug-loaded nanoparticles and application thereof

By preparing hypoxia and pH dual-responsive nanocarriers and utilizing the reaction of aldehyde benzoic acid, nonaglycone and azobenzene, the problems of low targeting and drug utilization of existing nanocarriers were solved, and drug delivery with high drug loading and high bioavailability was achieved, reducing toxic side effects.

CN119971056BActive Publication Date: 2025-10-17WUHAN UNIV OF TECH
2 Cites 0 Cited by

Patent Information

Application Number
CN202510095090.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-01-21
Publication Date
2025-10-17
Estimated Expiration
2045-01-21

AI Technical Summary

Technical Problem

Existing drug delivery nanocarriers have problems such as poor targeting, low drug bioavailability, and poor drug loading, and commonly used lysosomal membrane permeability inducers are not selective enough, leading to drug resistance and toxic side effects.

Method used

By using p-formylbenzoic acid, nonaglycone and azobenzene to react, a nanocarrier with moderate particle size and dual response to hypoxia and pH was prepared. It specifically targets the tumor site, releases drugs and covalently links to proteins on the lysosomal membrane, causing membrane rupture, increasing permeability and improving drug bioavailability.

Benefits of technology

The nanocarrier achieves high drug loading capacity and high drug bioavailability, reduces toxic side effects, and significantly improves tumor cell targeting and drug delivery efficiency.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a low-oxygen and pH dual-response nano-carrier, a drug-loaded nanoparticle and application thereof, and belongs to the technical field of biological medicines. The nano-carrier with moderate particle size and low-oxygen and pH dual-response is obtained by using the reaction of aldehyde benzoic acid, nonaethylene glycol and azo-p-phenetidine, the nano-carrier is specifically targeted to a tumor site, and then specifically releases drugs, thereby reducing toxic side effects; meanwhile, after the nano-carrier responds, benzaldehyde groups are released, the benzaldehyde groups are covalently connected with proteins on a lysosome membrane, the structure and activity of the proteins are changed, the lysosome membrane is broken after the proteins are denatured, the permeability of the lysosome membrane is increased, the nano-carrier cannot be discharged to the extracellular, the drug concentration in cells is greatly improved, and the drug bioavailability of the nano-carrier is significantly improved; in addition, the drug loading capacity of the nano-carrier is high, and therefore, the nano-carrier has a good application prospect.
Need to check novelty before this filing date? Find Prior Art